Your browser doesn't support javascript.
loading
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
Emmett, Louise; Papa, Nathan; Hope, Thomas A; Fendler, Wolfgang; Calais, Jeremie; Burger, Irene; Eiber, Matthias; Barbato, Francesco; Moon, Daniel; Counter, William; John, Nikeith; Xue, Alan; Franklin, Anthony; Thompson, James; Rasiah, Kris; Frydenberg, Mark; Yaxley, John; Buteau, James; Agrawal, Shikha; Ho, Bao; Nguyen, Andrew; Liu, Victor; Lee, Jonathan; Woo, Henry; Hsiao, Edward; Sutherland, Thomas; Perry, Elyse; Stricker, Phillip; Hofman, Michael S; Kasivisvanathan, Veeru; Roberts, Matthew; Murphy, Declan.
Afiliação
  • Emmett L; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Papa N; Garvan Institute of Medical Research, Sydney, Australia.
  • Hope TA; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Fendler W; Garvan Institute of Medical Research, Sydney, Australia.
  • Calais J; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Burger I; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Eiber M; Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California.
  • Barbato F; Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland.
  • Moon D; Department of Nuclear Medicine, School of Medicine, Technical University Munich, Munich, Germany.
  • Counter W; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • John N; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Xue A; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Franklin A; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Thompson J; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Rasiah K; Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.
  • Frydenberg M; Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Yaxley J; Garvan Institute of Medical Research, Sydney, Australia.
  • Buteau J; Department of Urology, St Vincent's Hospital Sydney, Sydney, Australia.
  • Agrawal S; Royal North Shore Hospital, Sydney, Australia.
  • Ho B; Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.
  • Nguyen A; The Wesley Hospital, Brisbane, Australia.
  • Liu V; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Department of Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer, Melbourne, Australia.
  • Lee J; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Woo H; Garvan Institute of Medical Research, Sydney, Australia.
  • Hsiao E; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Sutherland T; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Perry E; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Stricker P; Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Hofman MS; Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
  • Kasivisvanathan V; Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
  • Roberts M; Department of Radiology, St Vincent's Hospital, Melbourne, Australia.
  • Murphy D; Department of Radiology, St Vincent's Hospital, Melbourne, Australia.
J Urol ; 212(2): 299-309, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38758680
ABSTRACT

PURPOSE:

The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY score (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (International Society of Urological Pathology [ISUP] ≥2) incorporating separately read PI-RADS and PRIMARY scores, with external validation. MATERIALS AND

METHODS:

Two datasets of men with suspected PCa, no prior biopsy, recent MRI and 68Ga-PSMA-11-PET/CT, and subsequent transperineal biopsy were evaluated. These included the development sample (n = 291, 56% csPCa) a prospective trial and the validation sample (n = 227, 67% csPCa) a multicenter retrospective database. Primary outcome was detection of csPCa (ISUP ≥2), with ISUP ≥ 3 cancer detection a secondary outcome. Score performance was evaluated by area under the curve, sensitivity, specificity, and decision curve analysis.

RESULTS:

The 5-point combined (P) score was developed in a prospective dataset. In the validation dataset, csPCa was identified in 0%, 20%, 52%, 96%, and 100% for P score 1 to 5. The area under the curve was 0.93 (95% CI 0.90-0.96), higher than PI-RADS 0.89 (95% CI 0.85-0.93, P = .039) and PRIMARY score alone 0.84 (95% CI 0.79-0.89, P < .001). Splitting scores at 1/2 (negative) vs 3/4/5 (positive), P score sensitivity was 94% (95% CI 89-97) compared to PI-RADS 89% (95% CI 83-93) and PRIMARY score 86% (95% CI 79-91). For ISUP ≥ 3, P score sensitivity was 99% (95% CI 95-100) vs 94% (95% CI 88-98) and 92% (95% CI 85-97) for PI-RADS and PRIMARY scores respectively. A maximum standardized uptake value > 12 (P score 5) was ISUP ≥ 2 in all cases with 93% ISUP ≥ 3.

CONCLUSIONS:

The P score is easily calculated and improves accuracy for csPCa over both PI-RADS and PRIMARY scores. It should be considered when PSMA-PET is undertaken for diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article